ABOUT US
VCARE PHARMATECH
Jiangsu Vcare PharmaTech Co., Ltd.(Jiangsu Vcare),founded in 2010, is a high‑tech biopharmaceutical enterprise oriented toward meeting clinical needs through differentiation and dedicated to the development of innovative drugs and leading therapies. Following 16 years of sound development, the Company has established a group‑based operation and management system. Since its founding, the Company has focused on independent R&D of innovative drugs, rolled out strategic initiatives targeting clinical needs for severe and life‑threatening diseases including cardiovascular and cerebrovascular disorders, and gradually expanded into therapeutic areas such as oncology and autoimmune diseases. Its R&D team keeps advancing core pharmaceutical technologies throughout innovative drug development, accumulating extensive experience and robust technical capabilities in drug development.
INNOVATIVE DRUGS
Jiangsu Vcare's proprietary innovative drug R&D business adheres to a differentiated strategy addressing unmet clinical needs. Based on innovative approaches including "overcoming therapeutic resistance", "resolving drug resistance", and "enhancing target selectivity", the company has established a tiered pipeline architecture centered on Vicagrel. Currently, it possesses five Class I innovative drugs in clinical development: VC004 capsules (oral anti-tumor targeted therapy); Vicagrel capsules (oral anti-thrombotic agent); VC005 tablets (oral immunomodulatory and anti-inflammatory agent); VC005 gel (topical immunomodulatory and anti-inflammatory formulation). Additionally, multiple preclinical projects are progressing through the pipeline, with therapeutic focuses spanning cardiovascular/cerebrovascular diseases, oncology, and autoimmune/inflammatory disorders. This strategic portfolio positions the company for comprehensive coverage of global pharmaceutical markets in the future.
INNOVATION FOR A HEALTHIER FUTURE
Centered on innovative‑drug R&D, it will keep incubating more Class‑1 innovative drug candidates that resolve clinical demands via differentiated approaches. Through pharmaceutical innovation, it safeguards public health and strives toward its corporate vision.
NEWS
2026-11-12
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has officially launched a clinical trial for the new indication of bone metastatic cancer pain of Eratrectinib Capsules (VELMARTO®, VC004), a Class 1 innovative drug independently developed by the company. This move further expands the clinical application scope of this next-generation TRK inhibitor and explores an innovative treatment option for patients suffering from bone metastatic cancer pain.
2026-10-29
Recently, VC005 topical gel,balanced, highly selective new-generation JAK1 inhibitor, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially received the IND clearance from the NMPA. It is intended for the topical treatment of seborrheic dermatitis.
2026-10-22
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) recently announced that its self-developed VC005 topical gel, balanced, highly selective new-generation JAK1 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and adolescents, has successfully completed full participant enrollment in its Phase III clinical trial. This milestone marks steady progress for the topical product toward the NDA.
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn